News & Updates
Last week we had a great opportunity to interview Jacob Levenson, CEO of Map Health Management, of Austin, Texas. We focused our conversation on the importance of technology and data in population health---understanding where we are coming from and where we’re are going with this sea of data!
MAP ANNOUNCES PARTNERSHIP WITH INTENT SOLUTIONS TO ASSESS MEDICATION COMPLIANCE IN PATIENTS WITH ADDICTION
MAP Health Management, LLC., announced today a partnership with Intent Solutions designed to track adherence to medication protocols for patients with a Substance Use Disorder diagnosis who are served by MAP’s patient engagement technology. Intent Solutions is the creator of the TAD™, a biometric pill dispensation device that can track in real-time who has or has not taken their medication.
The partnership will launch with a pilot program as early as March of this year wherein a number of patients whose risk for relapse is continuously measured by MAP’s technology will be provided a TAD™ device. The device will send real-time data to MAP’s platform when a patient takes their medication, or fails to do so. With this information, MAP can inform the appropriate members of collaborative care networks if a patient is overusing their medication, or failing to take their medication at all. This information is then leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other modes of mitigating recidivism and costly treatment episodes.
INTENT SOLUTIONS™ ANNOUNCES NEW ADVISORY BOARD MEMBER
David R. Gastfriend, M.D. to Bring Pharma-Tech Knowledge
ATLANTA (January 17, 2017) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of David R. Gastfriend, M.D., chief architect of CONTINUUM, the American Society of Addiction Medicine’s standardized treatment software, to its Advisory Board. Gastfriend brings a vast wealth of pharma-tech experience from his work at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for the treatment of alcohol and opioid dependence. Most recently, Gastfriend co-founded DynamiCare Health, Inc., a technology start-up that focuses on incentivizing patients for compliance on treatments. As a clinical scientist in addiction, he will assist in helping Intent Solutions optimize TAD for improving patient adherence, as well as advise the company on leveraging the various stakeholders in the healthcare system to achieve change and improvements in patient outcomes.
Clinical Trials Insight: "Adherence Data Gets Smart"
The very definition of is on the brink of change because of new technologies, sensors and real-time data. Intent Solutions is a part of a major shift in the digital health economy where the ability to monitor and stream vast sets of new, real-time data in clinical research and health delivery will reveal how and when people take medications.
Intent Solutions Looks to Expand Market
DECEMBER 6, 2016 BY KATHY DION
ATLANTA – With $1.5 million in new funding on the books, Intent Solutions aims to expand the market for its TAD smart medication dispenser technology.
TAD has been attracting attention from big specialty pharmaceutical companies recently and Sam Zamarripa, president/director of Intent Solutions, hopes to work with them on clinical research to expand the market for the device.
INTENT SOLUTIONS™ RAISES $1.5 MILLION IN SEED CAPITAL
Announces first equity round of financing to drive growth in 2017
ATLANTA (November 11, 2016) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, announced today that is has successfully completed a seed round of funding of $1.5 million.
TAD, for “Take As Directed,” is a smart, mobile, medication dispenser that helps patients obtain better health outcomes by helping the right patient take the right dose at the right time. TAD, which can be programmed to a specific regimen and schedule, incorporates biometric access and is fully tamper resistant. The medication dispenser also records adherence data, which is sent to a cloud database for analysis, reducing errors and simplifying data reconciliation for clinical trials.
Intent Solutions raises $1.5M for connected device aimed at medication adherence, abuse prevention
By Jonah Comstock | November 14, 2016
Intent Solutions, an Atlanta-based company working on a connected medication dispenser called TAD, has raised $1.5 million in seed funding. The company did not disclose the investors.
INTENT SOLUTIONS™ ANNOUNCES NEW ADVISORY BOARD MEMBER
Chris Hassan to Bring Vast Patient Care and Treatment Knowledge
ATLANTA (October 19, 2016) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of Chris Hassan, previous CEO at Colonial Management Group, LP, to its Advisory Board. Hassan brings a vast wealth of knowledge from his years overseeing the treatment and medication of tens of thousands of patients with opioid use disorder at Colonial Management Group, LP. Moreover, Hassan has been on the front edge of drug development for major pharmaceuticals including Depot Naltrexone, as well as the commercial introduction of Buprenorphine in the US, which is now the standard of care in office based opioid treatment. As an expert on drug abuse science, he will advise Intent Solutions on issues including TADs ability to help treat opioid use disorder.